Pneumococcal Vaccination Market Size, Share, Growth, and Industry Analysis, By Type (PPSV 23,PCV 7/13,PCV 10), By Application (Child,Adult), Regional Insights and Forecast to 2035

Pneumococcal Vaccination Market Overview

The global Pneumococcal Vaccination Market in terms of revenue was estimated to be worth USD 10172.83 Million in 2026 and is poised to reach USD 16500.48 Million by 2035, growing at a CAGR of 5.52% from 2026 to 2035.

The Pneumococcal Vaccination Market Report indicates that in the United States, approximately 65 400 000 adults aged ≥ 65 received one dose of any pneumococcal vaccine in 2021, with 65.8 % coverage in that group.

Coverage in adults aged 19–64 with risk factors was 22.2 %, with differences among ethnic groups: 23.3 % White, 19.0 % Hispanic, 16.9 % Asian. Annual invasive pneumococcal disease incidence was estimated at 165 per 100 000 infants <12 months and 203 per 100 000 in children aged 12–23 months. Third‑dose PCV coverage globally reached 67 % in 2024 across 163 countries, and the USA remains a leading contributor to uptake and immunization campaigns.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver:25 % share of pneumococcal vaccines in 2024 held by conjugate vaccines segment.
• Major Market Restraint:2 % pneumococcal vaccination uptake among at‑risk adults aged 19–64 in 2021.
• Emerging Trends: PCV segment projected to hold 60.7 % share in global pneumococcal vaccines market in 2025.
• Regional Leadership: North America contributed 40.56 % of global pneumococcal vaccines market share in 2024.
• Competitive Landscape: Prevnar 13 held 42.22 % product type share in 2024.
• Market Segmentation: Adults aged ≥ 65 held 53.23 % age‑group share in 2024.
• Recent Development: FDA approved Capvaxive targeting 21 serotypes in June 2024.

Pneumococcal Vaccination Market Latest Trends

The Pneumococcal Vaccination Market Analysis highlights that in 2024 the pneumococcal conjugate vaccine (PCV) segment commanded approximately 65 % share of the total vaccine uptake, surpassing polysaccharide vaccines by more than 25 percentage points. The adult segment represented over 53 % of overall market share in 2024, reflecting substantial focus on immunizing those aged ≥ 50. Uptake among adults aged ≥ 65 was about 65.8 %, while at‑risk adults 19–64 recorded only 22.2 % coverage. The introduction of Prevnar 20 in April 2023 and Capvaxive in June 2024 expanded serotype coverage to 20 and 21 respectively, affecting vaccine mix. PCV15 and PCV20 are now integrated into US child immunization schedules with a four‑dose series scheduled at 2, 4, 6 and 12–15 months. By 2024, third‑dose vaccination coverage reached 67 % globally across 163 Member States. Emerging pipelines such as protein‑based VAX‑31 are advancing Phase 3 trials after involving 1 015 adults aged ≥ 50.

Pneumococcal Vaccination Market Dynamics

The Pneumococcal Vaccination Market Dynamics section provides a data-driven examination of the key factors influencing market performance. Globally, conjugate vaccines accounted for approximately 65.25 % of the total market share in 2024, with adult vaccination coverage in the United States reaching 65.8 % for adults aged ≥ 65 and only 22.2 % among at-risk adults aged 19–64. Incidence rates of invasive pneumococcal disease remain high at 165 per 100 000 infants under 12 months and 203 per 100 000 in children 12–23 months, underscoring the importance of vaccination programs. New regulatory expansions in October 2024 increased vaccine eligibility to all adults aged ≥ 50, significantly widening the target population by tens of millions. This section quantifies the impact of drivers such as new product approvals, restraints such as low adult vaccine uptake, opportunities including high pediatric vaccine coverage, and challenges such as inequity in coverage (e.g., 70.1 % White vs. 46.2 % Hispanic uptake among seniors).

DRIVER

"Rising PCV uptake driven by expanded serotype coverage and adult immunization recommendations."

A shift toward higher‑valent PCVs such as PCV20 and PCV21 led to more than 65 % global share for conjugate vaccines in 2024. In the USA, adult coverage among those ≥ 65 was 65.8 %, driving demand for adult formulas. The four‑dose series for children under five with PCV15 or PCV20 ensures high pediatric uptake. The PCV segment held 60.7 % share projected in 2025. Continuous FDA approvals, like Prevnar 20 in 2023 and Capvaxive in 2024, expanded target populations and provider recommendation policies. These factual metrics reflect solid Pneumococcal Vaccination Market Growth fundamentals as captured in Pneumococcal Vaccination Market Size analysis for B2B stakeholders.

RESTRAINT

"Low pneumococcal vaccination uptake among at""‑risk adult populations."

Despite strong pediatric coverage, only 22.2 % of adults aged 19–64 with risk conditions had received pneumococcal vaccine by 2021. Uptake disparity by ethnicity (23.3 % White, 19.0 % Hispanic, 16.9 % Asian) indicates systemic gap. Only 65.8 % of adults aged ≥ 65 were covered overall, leaving roughly 34 % unvaccinated. Adult vaccination uptake remains the weak link restraining the Pneumococcal Vaccination Industry Report. These figures underline resistance to full implementation of adult programs, representing a factual restraint in Pneumococcal Vaccination Market Analysis for decision‑makers evaluating opportunities.

OPPORTUNITY

"Expanded adult immunization recommendations at age 50 and risk""‑based expansion."

In October 2024 recommendations expanded so that all adults aged ≥ 50 are eligible for a single PCV dose if PCV‑naïve. This policy extended target population by tens of millions. Annual IPD incidence in infants < 12 months is 165 cases per 100 000 and in children 12–23 months is 203 per 100 000, indicating pediatric need remains high. Global third‑dose PCV coverage at 67 % across 163 countries in 2024 demonstrates room for higher adoption. New 21‑valent and 31‑valent vaccines in development signal future pipeline expansion. These statistics present investment opportunity points in Pneumococcal Vaccination Market Opportunities for B2B investors.

CHALLENGE

"Serotype replacement and immunization equity gaps."

The emergence of non‑vaccine serotypes post‑PCV13 implementation urges development of PCV20 and PCV21. Immunization inequities, with coverage rates in adults aged ≥ 65 at 70.1 % in White versus 54.8 % Black, 46.2 % Hispanic and 55.8 % Asian highlight demographic disparity. Only 1.2 % of adults ≥ 65 had ever received PCV13 in early years. Uptake among at‑risk adults 19–64 was only 22.2 %. These demographic coverage and serotype evolution issues represent factual challenges in Pneumococcal Vaccination Market Challenges section of a Pneumococcal Vaccination Market Outlook and B2B report.

Pneumococcal Vaccination Market Segmentation

The Pneumococcal Vaccination Market Segmentation section analyzes the market structure by type and application. By type, PPSV23 is widely used in adults aged ≥ 50 and covers 23 serotypes, PCV13 accounted for 42.22 % of the product-type share in 2024 with 46 % efficacy against pneumococcal pneumonia and 75 % against invasive disease, while PCV10 accounted for only 8 % of the market in Germany in 2018, showing limited uptake. By application, pediatric vaccination programs deliver 67 % global coverage for the third dose in 2024 across 163 countries, with IPD incidence of 165 to 203 per 100 000 in children under 2 years. Adult immunization remains a focus, with adults ≥ 65 contributing 53.23 % of the market share and at-risk adult populations (19–64 years) showing only 22.2 % coverage.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

PPSV 23: The polysaccharide vaccine covers 23 serotypes and is approved in the USA for people aged ≥ 50 or ≥ 2 with risk. It does not induce T‑cell memory, and immunity may wane, requiring revaccination at 65 if initial dose was given earlier. Uptake among adults ≥ 65 includes PPSV23 often in series with PCV15. Canadian HIV patients saw incidence drop from 768 to 244 per 100 000 after PPSV23 usage.

The PPSV 23 vaccine type segment reached an estimated market size of USD 2,150 million in 2025, holding 22 % of the global share, and is forecast to expand steadily at a 5.5 % CAGR during 2025–2034.

Top 5 Dominant Countries in the PPSV 23 Segment

• United States: In 2025, the PPSV 23 segment in the United States was valued at USD 720 million with 33 % national share and is projected to grow at 5.3 % CAGR throughout the forecast period.
• Germany: Germany’s PPSV 23 market segment was valued at USD 230 million with 11 % share in 2025, expanding consistently with a CAGR of 5.4 % between 2025 and 2034 driven by adult immunization coverage.
• Japan: Japan recorded a PPSV 23 segment size of USD 210 million, representing 10 % share in 2025, with expected market growth maintained at 5.6 % CAGR driven by nationwide adult immunization programs.
• United Kingdom: The PPSV 23 market in the United Kingdom accounted for USD 190 million with 9 % market share in 2025 and is forecast to grow at a CAGR of 5.2 % over the next nine years.
• Canada: Canada’s PPSV 23 market was valued at USD 165 million with 8 % share in 2025, anticipated to progress at a steady CAGR of 5.5 % through 2034 driven by high-risk population vaccination uptake.

PCV 13 (PCV7/13): PCV13 demonstrated efficacy of 46 % against pneumococcal pneumonia and 75 % efficacy against IPD in adults ≥ 65 in a trial of ~85 000 participants. It held a 42.22 % product type share in 2024. Pediatric incidence rates of 165‑203 per 100 000 underlined need for PCV13 in children.

The PCV 7/13 vaccine type segment reported an estimated market size of USD 3,850 million in 2025, commanding a 40 % global share, and is expected to achieve a consistent CAGR of 5.4 % from 2025 to 2034.

Top 5 Dominant Countries in the PCV 7/13 Segment

• United States: The PCV 7/13 segment in the United States was valued at USD 1,420 million in 2025, contributing a dominant 37 % share with an expected CAGR of 5.2 % driven by broad immunization coverage.
• France: France held a PCV 7/13 market value of USD 250 million in 2025 with a 6 % share and is forecast to grow at a CAGR of 5.5 % through increasing childhood vaccination programs.
• Australia: The PCV 7/13 segment in Australia was valued at USD 200 million with a 5 % share in 2025 and is anticipated to grow at 5.6 % CAGR due to active pediatric immunization initiatives.
• Italy: Italy recorded a PCV 7/13 market size of USD 175 million, holding a 4.5 % share in 2025 and expanding with a CAGR of 5.3 % through ongoing preventive healthcare strategies.
• Spain: Spain’s PCV 7/13 market size in 2025 was USD 160 million with a 4.2 % share, showing a projected CAGR of 5.4 % supported by robust vaccination policies for infants and adults.

PCV 10: In Germany in 2018, PCV10 held only 8 % market share, making it minimal compared to PCV13/15/20. Its role remains limited in high‑income markets, though targeted use exists in selected pediatric immunization programs.

The PCV 10 vaccine type accounted for an estimated market size of USD 1,530 million in 2025, contributing 16 % global share, with an expected 5.7 % CAGR during the 2025–2034 forecast period.

Top 5 Dominant Countries in the PCV 10 Segment

• India: The PCV 10 segment in India reached USD 480 million with 31 % share in 2025 and is projected to grow at 5.8 % CAGR driven by ongoing childhood immunization campaigns.
• Brazil: Brazil’s PCV 10 market was USD 300 million with 19 % share in 2025 and is forecast to grow at 5.7 % CAGR driven by national vaccination strategies.
• Mexico: Mexico recorded a PCV 10 market size of USD 180 million with 12 % share in 2025, progressing steadily at a 5.6 % CAGR during the period 2025 to 2034.
• South Korea: South Korea’s PCV 10 market was valued at USD 150 million with 10 % share in 2025 and is projected to grow at 5.5 % CAGR in the forecast timeframe.
• Thailand: Thailand accounted for a PCV 10 market size of USD 120 million with 8 % share in 2025 and a projected CAGR of 5.7 % over the coming years.

BY APPLICATION

Child Application: ACIP recommends a four‑dose series of PCV15 or PCV20 at ages 2, 4, 6 and 12–15 months. Pediatric IPD incidence was 165 per 100 000 for < 12 months and 203 per 100 000 for 12–23 months. Global third‑dose PCV coverage reached 67 % by 2024. These figures translate into sustained Pediatric segment share in the Pneumococcal Vaccination Market Size and Market Research Report context.

The child application segment achieved a market size of USD 4,500 million in 2025, holding 47 % of the global market share, with an expected CAGR of 5.6 % throughout the forecast period.

Top 5 Dominant Countries in the Child Segment

• United States: In 2025, the child application segment in the United States was valued at USD 1,700 million with 38 % share and is projected to grow at 5.4 % CAGR supported by strong routine immunization.
• China: The child segment in China reached USD 1,200 million in 2025, securing 27 % share, and is expected to expand at 5.7 % CAGR owing to rapid immunization programs across provinces.
• India: India recorded a child segment size of USD 600 million with 13 % share in 2025, with expected growth at 5.8 % CAGR driven by government-funded vaccination programs.
• Russia: Russia’s child segment was valued at USD 300 million with 7 % share in 2025 and is forecast to grow steadily at 5.5 % CAGR.
• Brazil: Brazil held a child application market size of USD 250 million with 6 % share in 2025, and the CAGR is forecast at 5.6 % for the coming years.

Adult Application: In 2021, 65.8 % of adults aged ≥ 65 received ≥ 1 pneumococcal vaccine dose; coverage among adults 19–64 with risk conditions was only 22.2 %. Ethnic disparities observed: 70.1 % White vs. 54.8 % Black vs. 46.2 % Hispanic vs. 55.8 % Asian. Expanded ≥ 50 recommendation in October 2024 increased eligibility by tens of millions. Adult application remains dominant, representing over 53 % share in 2024.

The adult application segment accounted for USD 5,140 million in 2025, representing 53 % global share, and is forecast to grow at a CAGR of 5.5 % through 2034.

Top 5 Dominant Countries in the Adult Segment

• United States: In 2025, the adult segment in the United States was valued at USD 2,000 million with 39 % share, expected to grow at 5.3 % CAGR.
• Germany: Germany recorded an adult segment size of USD 300 million with 6 % share in 2025 and projected growth of 5.4 % CAGR.
• Japan: Japan’s adult segment was valued at USD 280 million with 5.4 % share in 2025 and is forecast to grow at 5.6 % CAGR.
• United Kingdom: The UK adult market segment accounted for USD 250 million with 4.9 % share in 2025, projected to grow at 5.2 % CAGR.
• France: France recorded an adult application size of USD 240 million in 2025 with 4.7 % share and a CAGR of 5.5 %.

Regional Outlook for the Pneumococcal Vaccination Market

The Regional Outlook section highlights geographical performance patterns. North America led the global market with 40.56 % share in 2024, supported by high adult coverage (65.8 % among seniors) and recent FDA approvals of PCV20 in 2023 and PCV21 in 2024. Europe shows strong vaccine adoption, with PCV conjugate vaccines exceeding 60 % of the regional market share and new product authorizations expanding adult coverage. Asia-Pacific is emerging as the fastest-growing region, driven by a third-dose PCV coverage of 88 % in South-East Asia in 2024 and the presence of regional manufacturers such as WALVAX, Bio Kangtai, and Sinovac. Middle East & Africa remain underpenetrated, with PCV introduced in 163 countries but only 67 % global average coverage, highlighting disparities and significant growth potential in these regions.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

North America held approximately 40.56 % of global pneumococcal vaccines market share in 2024, with the USA accounting for a significant share. Coverage among US adults ≥ 65 was 65.8 %, and among at‑risk adults 19–64 was 22.2 %. Expanded age‑based recommendation to ≥ 50 in October 2024 and FDA approvals of Capvaxive and Prevnar 20 broadened adult vaccine types. Prevnar 13 held 42.22 % product share in 2024. Global PCV conjugate vaccine share was about 65 %, and adult segment share was 53.23 % in this region.

North America’s pneumococcal vaccination market was valued at USD 3,850 million in 2025, capturing close to 40 % of the global market share, and is projected to grow steadily at a 5.4 % CAGR through 2034, supported by high adult vaccination coverage, comprehensive immunization schedules, strong healthcare infrastructure, and consistent adoption of newer vaccines such as PCV20 and PCV21 that address a wider range of pneumococcal serotypes.

Major Dominant Countries in North America

• United States: In 2025, the United States pneumococcal vaccination market was valued at USD 3,200 million, accounting for an 83 % share of the regional market, and is forecast to grow at a CAGR of 5.3 % due to robust vaccination programs, policy-driven uptake, and advanced healthcare delivery systems.
• Canada: Canada reached a pneumococcal vaccination market size of USD 330 million in 2025, representing an 8.6 % regional share, and is expected to grow at a CAGR of 5.5 % over the forecast period as a result of strong adult and pediatric vaccination initiatives.
• Mexico: The pneumococcal vaccination market in Mexico achieved USD 180 million in 2025, which equals 4.7 % of the total North American share, with an anticipated CAGR of 5.6 % driven by government-backed immunization campaigns and expanding healthcare access for at-risk groups.
• Puerto Rico: Puerto Rico recorded a market size of USD 100 million for pneumococcal vaccination in 2025, capturing approximately 2.6 % of the regional share, and is projected to grow at 5.4 % CAGR through 2034 supported by improved vaccination coverage and healthcare outreach efforts.
• Costa Rica: Costa Rica’s pneumococcal vaccination market in 2025 stood at USD 40 million with a 1 % share of the North American region and is expected to advance at a CAGR of 5.7 %, benefiting from strengthened immunization infrastructure and child health programs.

EUROPE

Europe has strong national immunization programs. PCV uptake varies: PCV10 had 8 % share in Germany in 2018; PCV13 and higher valents dominate. EMA granted authorization for PCV20 and PCV21 vaccines in 2022 and 2025. PCV conjugate vaccine adoption likely exceeds 60 % share region‑wide.

Europe’s pneumococcal vaccination market was valued at USD 2,900 million in 2025, capturing around 30 % of the global share, and is projected to expand steadily at a CAGR of 5.5 % through 2034, supported by well-established national immunization programs, comprehensive adult and pediatric vaccination policies, strong awareness campaigns, and a consistent supply of advanced vaccines across the region.

Major Dominant Countries in Europe

• Germany: In 2025, Germany’s pneumococcal vaccination market reached USD 650 million, representing 22 % of the regional share, and is forecast to grow at a CAGR of 5.4 % driven by widespread vaccination mandates, high healthcare spending, and extensive coverage across both adult and child populations.
• France: France recorded a pneumococcal vaccination market size of USD 550 million in 2025 with a 19 % regional share and is projected to grow at 5.5 % CAGR due to strong immunization programs and consistent healthcare funding that drives demand across all risk groups.
• United Kingdom: The United Kingdom’s pneumococcal vaccination market was valued at USD 520 million in 2025, with 18 % of the European share, and is expected to expand at 5.3 % CAGR driven by preventive healthcare strategies and expanding vaccination recommendations for adults.
• Italy: Italy reached a market size of USD 400 million in 2025, accounting for 14 % of the regional market, and is forecast to grow at 5.6 % CAGR supported by increasing vaccine awareness, pediatric coverage, and integration of PCV20 into routine schedules.
• Spain: Spain’s pneumococcal vaccination market was valued at USD 350 million in 2025, contributing 12 % to Europe’s share, and is projected to grow at 5.5 % CAGR through robust public immunization programs and rising adoption of high-valent vaccines in the healthcare system.

ASIA‑PACIFIC

Asia‑Pacific features rapid expansion with local manufacturers. Third‑dose PCV coverage in South‑East Asia region reached 88 % in 2024. Countries like China with Sinovac and WALVAX producing PCV contribute to domestic supply. Adult coverage remains variable, with pediatric coverage high. Asia‑Pacific is the fastest-growing region in pneumococcal vaccination.

Asia-Pacific’s pneumococcal vaccination market was valued at USD 2,400 million in 2025, holding about 25 % of the global market share, and is expected to grow at a CAGR of 5.6 % through 2034, supported by rapidly expanding healthcare infrastructure, strong government-led immunization campaigns, local vaccine manufacturing, and large-scale pediatric vaccination programs.

Major Dominant Countries in Asia-Pacific

• China: China’s pneumococcal vaccination market in 2025 was valued at USD 1,000 million, accounting for 42 % of the regional share, and is projected to grow at a CAGR of 5.7 % due to massive immunization campaigns and broadening vaccine availability in both urban and rural areas.
• India: India recorded a pneumococcal vaccination market size of USD 650 million in 2025 with 27 % of the regional share, and is expected to grow at 5.8 % CAGR driven by expanded government programs for childhood and risk-group vaccinations.
• Japan: Japan’s pneumococcal vaccination market was valued at USD 300 million in 2025 with 12 % of Asia-Pacific’s share and is forecast to grow at 5.5 % CAGR, supported by universal healthcare access and high vaccination awareness levels.
• South Korea: South Korea accounted for USD 200 million of the regional market in 2025, with an 8 % share, and is anticipated to grow at a CAGR of 5.6 % due to comprehensive preventive healthcare policies and national immunization programs.
• Thailand: Thailand’s pneumococcal vaccination market reached USD 150 million in 2025, holding 6 % of the Asia-Pacific share, and is projected to grow at 5.7 % CAGR supported by government-led initiatives and partnerships that expand pediatric and adult vaccination coverage.

MIDDLE EAST & AFRICA

By end of 2024, 163 countries introduced PCV and global third‑dose coverage was 67 %. However, coverage in parts of the Middle East and Africa remains below global average. Immunization programs rely heavily on international support. Adult coverage remains very low, while pediatric programs dominate uptake.

The Middle East and Africa pneumococcal vaccination market was valued at USD 990 million in 2025, representing 10 % of the global share, and is anticipated to grow at 5.6 % CAGR through 2034, driven by international vaccine alliance support, gradual improvements in healthcare delivery, and rising awareness of preventive immunization in both urban and rural populations.

Major Dominant Countries in Middle East & Africa

• Saudi Arabia: In 2025, Saudi Arabia’s pneumococcal vaccination market was valued at USD 220 million with a 22 % share of the regional market and is expected to grow at 5.5 % CAGR due to expanding immunization campaigns and significant government investment in healthcare.
• South Africa: South Africa recorded a market size of USD 180 million in 2025, representing 18 % of the region’s share, and is forecast to grow at 5.6 % CAGR as healthcare accessibility improves and vaccination programs expand for infants and adults.
• Egypt: Egypt’s pneumococcal vaccination market in 2025 stood at USD 150 million with 15 % share and is projected to grow at 5.7 % CAGR due to targeted national vaccination campaigns and partnerships with international health organizations.
• UAE: The UAE reached a pneumococcal vaccination market size of USD 120 million in 2025, with a 12 % share, and is forecast to grow at 5.6 % CAGR driven by high-quality healthcare infrastructure and mandatory preventive healthcare initiatives.
• Nigeria: Nigeria’s pneumococcal vaccination market was valued at USD 100 million in 2025, accounting for 10 % of the regional market, and is expected to grow at 5.5 % CAGR due to increasing government initiatives to strengthen immunization among children and at-risk populations.

List of Top Pneumococcal Vaccination Companies

• MSD
• WALVAX
• Bio Kangtai
• GSK
• Sinovac
• CDIBP
• Pfizer
• Sanofipasteur

Pfizer: Held 42.22 % product type share with Prevnar 13 in 2024 and dominates the adult PCV market. Prevnar 20 approval in 2023 strengthened leadership.

Merck (MSD): Holds significant share via Vaxneuvance and Pneumovax 23. Capvaxive approval in June 2024 targeting 21 serotypes strengthens its position.

Investment Analysis and Opportunities

The Pneumococcal Vaccination Market Research Report highlights strong investment opportunities. Adult ≥ 50 recommendation increased eligibility by tens of millions, and global third‑dose PCV coverage at 67 % leaves a 33 % gap for children. Pipelines like VAX‑31 (31‑valent) in Phase 3 trials with 1 015 adults aged ≥ 50 show potential for premium products. North America’s 40.56 % global share indicates stable growth, while Asia‑Pacific’s strong domestic vaccine production and 88 % coverage in South‑East Asia indicate opportunities for scalable expansion. Adult vaccination coverage rates of 65.8 % (≥ 65) and 22.2 % (19–64 risk) reflect unmet needs, creating opportunities for new entrants and investors to close gaps.

New Product Development

Innovations include PCV15 (Vaxneuvance), PCV20 (Prevnar 20) approved April 2023, and PCV21 (Capvaxive) approved June 2024. PCV13 demonstrated 46 % efficacy against pneumococcal pneumonia and 75 % against invasive disease in adults ≥ 65 in a trial of 85 000 participants. VAX‑31 31‑valent vaccine in a study of 1 015 adults aged ≥ 50 offered broader protection, with superior immune responses against all serotypes covered. Expanded recommendations in 2024 included all adults ≥ 50, and new product authorizations in 2025 added competition to the market.

Five Recent Developments

• FDA approved Prevnar 20 in April 2023 covering 20 serotypes.
• FDA approved Capvaxive (PCV21) in June 2024 for adults ≥ 18 covering 21 serotypes.
• Age‑based PCV recommendations expanded in October 2024 to include all adults aged ≥ 
• EMA granted Capvaxive authorization in March 2025.
• VAX‑31 vaccine trial on 1 015 adults ≥ 50 showed superior immune response and is entering Phase 

Report Coverage of Pneumococcal Vaccination Market

The Pneumococcal Vaccination Market Research Report covers global and regional scope including North America (≈ 40.56 % share in 2024), Europe, Asia‑Pacific, and Middle East & Africa. It segments by vaccine type (PPSV23, PCV7/13, PCV10), application (child vs adult), and age group. Metrics include vaccine uptake percentages (65.8 % adult ≥ 65, 22.2 % at‑risk adults), product share data (PCV segment ~65 %, Prevnar 13 42.22 %), and coverage by region (global third‑dose coverage 67 %). Clinical efficacy data (PCV13 efficacy 46 % pneumonia, 75 % invasive disease) and pipeline analysis (VAX‑31 trial of 1 015 subjects) are included. It includes competitive landscape, regulatory approvals, recommendation changes, and demographic disparities. This supports B2B needs for Pneumococcal Vaccination Market Size, Market Share, Market Growth, Market Trends, Market Forecast, and Market Outlook.

Pneumococcal Vaccination Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 10172.83 Million in 2026
Market Size Value By	USD 16500.48 Million by 2035
Growth Rate	CAGR of 5.52% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : PPSV 23 PCV 7/13 PCV 10 By Application : Child Adult
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample